Skip to main content
OpenTrials
Completed

NCT Number: NCT01368146

Human Repeat Insult Patch Test of Wound Dressings

The purpose of this study is to determine whether contact sensitization occurs to the skin of normal healthy human subjects, by repetitive application of IV Clear™, Tegaderm CHG™ and Silicone Vehicle Control dressings.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Sensitization

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Hill Top Research

St. Petersburg, Florida, 33710, United States

About this study

A single center, within-subject randomized study design in healthy adult subjects. Qualified subjects will complete three phases of the study (induction, rest and challenge).

Data for irritation, adhesion and pain upon removal will be collected from the individual patch sites.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, 18 years or older
  • In good health, as determined by medical history and concomitant medication
  • Able to comprehend and sign informed consent
  • Unable to bear children or willing to use adequate birth control
  • Willing and able to follow study directions, to participate in the study and to return for all specific visit

Exclusion criteria

  • Subject pregnant, planning a pregnancy or lactating
  • Diabetes (any type)
  • Mastectomy involving removal of lymph nodes
  • Clinically significant skin disease, including but not limited to psoriasis, eczema, atopic dermatitis, and active cancer
  • Asthma or other severe respiratory disease requiring medication
  • Self-reported immunological disorders including (but not limited to) HIV positive, AIDS, rheumatoid arthritis, and systematic lupus erythematosus
  • Treatment of any type of cancer within the last two years or history of skin cancer in the test area
  • Use of any of the following: topically applied products (e.g. medicals, lotions, creams, etc.) at the application site within 3 days of first application of test articles, immunosuppressive drugs within 30 days of first application of test articles, systemic or topical corticosteroids within 30 days of first application of test articles, and systemic or topically applied anti-inflammatory and antihistamine medications within 3 days of first application of test articles
  • Participation in any patch test for irritation or sensitization within the last four weeks
  • Participation in any investigational drug study within the last four weeks
  • Damaged skin in or around the test sites which includes: sunburn, extremely deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfiguration
  • Known sensitization to adhesives, bandages, or materials used in test articles
  • Medical condition which, in investigator's judgment, makes the subject ineligible or places the subject at undue risk

Treatment and study plan

IV Clear™

Device

Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver

Tegaderm CHG™

Device

Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate

Silicone Vehicle Control Dressing

Device

Polyurethane film with silicone adhesive dressing, without antimicrobials

Primary outcomes

  1. Irritation

    Time frame: Assessed at induction phase (evaluated before reapplication; 9 applications over 3 weeks, reapplied after every 48 or 72 hrs) and challenge phase (single 48-hr application of test article to naive sites and evaluation 30 mins, 24 and 48 hrs post-removal

    Irritation assessed at the induction phase will be scored on a Berger and Bowman Scale. Irritation assessed at the challenge phase will be scored on a defined scale measuring erythema reactions, ranging from no reaction to strong erythema.

Secondary outcomes

  1. Adhesion

    Time frame: Assessed at each 72 hour evaluation over three weeks, and once for a single 48-hour challenge application

    Adhesion was scored as follows:

    0 = no lift from skin (≥90% adherence)

    • = some edges only lifting from skin (≥75% to ˂90% adherence)
    • = less than half of the test article lifing (≥50% to ˂75% adherence)
    • = more than half of the test article lifing but not detached (≥25% to ˂50% adherence)
    • = test article detached (0% adherence)

  2. Pain upon removal

    Time frame: Assessed by subjects at 72 hour evaluations over three weeks and a single 48-hour challenge application

    Any pain experienced during removal will be rated on a scale from 0 to 10, where 0 = no pain and 10 = worst possible pain.

Sponsors and collaborators

Lead sponsor

Covalon Technologies Inc.

Industry

Registry information

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Jun 7, 2011
Registry last updated
Feb 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.